Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of treating schizophrenia

a treatment method and schizophrenia technology, applied in the field of schizophrenia treatment, can solve the problems of abnormal levels of various neurochemicals and/or abnormal responsiveness to neurochemicals, adverse effects on higher level executive functions, and many dopamine antagonist antipsychotic drugs are not as effective at controlling “negative” symptoms, so as to improve cognitive function and improve cognitive deficits

Inactive Publication Date: 2006-12-28
TITAN PHARMA
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0018] In another embodiment, the invention provides methods for improving cognitive deficits associated with schizophrenia, particularly elderly schizophrenia patients. Cognitive deficits are treated by the administration of therapeutic cells, or a combination of therapeutic cells with protective cells and / or support cells, adhered to a support matrix, to the brain of a subject suffering from schizophrenia-associated cognitive deficits. Administration of the therapeutic cells results in an improvement in cognitive function in the subject.

Problems solved by technology

Psychiatric disorders, on the other hand, are the result of dysregulation of neurons, which can result in abnormal levels of various neurochemicals and / or abnormal responsiveness to neurochemicals.
However, although clopazine seems to ameliorate certain symptoms (e.g., verbal fluency, reaction time and attention), it appears to have an adverse effect on higher level executive functions, such as working memory ability and visual memory.
Moreover, many dopamine antagonist antipsychotic drugs are not as effective at controlling the “negative” symptoms, as compared to the “positive” symptoms of schizophrenia (Angrist et al., 1982, Psychopharm.
However, dopamine reuptake inhibitors oppose the effects of clopazine and other dopamine antagonists, potentially nullifying the activity of this group of drugs in the treatment of the positive symptoms of schizophrenia.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Treatment of the Negative Symptoms of Schizophrenia by Administration of RPE cells Adhered to a Support Matrix

[0087] Humans who have ingested PCP on a long term basis exhibit a large number of symptoms associated with schizophrenia, such as withdrawal, affective blunting, paranoia, delusions and hallucinations. This observation is the basis of an art accepted model of schizophrenia, which utilizes long term administration of phencyclidine (PCP) to vervet monkeys (Jentsch et al., supra)

[0088] Vervet monkeys (Cercopithecus aethiops sabaeus) are divided into three groups. The first group (“Control”) are given intramuscular (IM) saline injections bid, for 14 days. The second and third groups (“PCP−” and “PCP+”) are given 0.3 mg / kg PCP by IM injection, bid, for 14 days.

[0089] Human RPE cells are prepared according to the method of Lui et al. (1990, Investigative Ophthamol., ARVO Supplement). The cells are adhered to crosslinked gelatin microspheres (Cultispher-S®, mean diameter 120μm)...

example 2

Treatment of Tardive Dyskinesia by Administration of RPE Cells Adhered to a Support Matrix

[0092] Long term administration of Cebus monkeys with certain antipsychotic drugs provides a model for human EPS associated with antipsychotic drug therapy, particularly TD (Kovacic et al., 1982, J. Clin. Psychopharm. 2(5):305-307). Cebus monkeys treated with long term administration of fluphenazine exhibit classic TD symptoms, including rhythmic finger movements, movements analogous to human pacing, and oral symptoms such as rhythmic up and down motions of the jaw and tongue movements.

[0093]Cebus apella monkeys are treated to produce a model of TD, by long term administration of depot fluphenazine enanthate. Fluphenazine is administered biweekly, progressing from a low dose (0.1 mg / kg) to 3.2 mg / kg by six months. Treatment is continued for at least one year.

[0094] Activity of the monkeys is observed, with particularly attention to locomotor activity and signs of TD, to establish baseline le...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diametersaaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The invention provides methods for the treatment of abnormal psychiatric states, particularly the negative symptoms of schizophrenia and extrapyramidal side effects (EPS) of antipsychotic drugs. The inventive methods relate to the administration of therapeutic cells (which produce dopamine or dopamine precursors) adhered to support matrices to subjects suffering from the negative symptoms of schizophrenia and / or EPS. The therapeutic cells may be coadministered with cells which protect the therapeutic cells from immune rejection and / or cells which produce neurotrophic factors which improve the viability of the therapeutic cells.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a divisional of U.S. application Ser. No. 09 / 289,576, filed Apr. 9, 1999, which is herein incorporated by reference in its entirety.TECHNICAL FIELD [0002] The invention relates generally to the treatment of psychiatric disorders, and particularly to methods of treating negative symptoms of schizophrenia and / or certain extrapyramidal side effects (EPS) of antipsychotics by administering an effective number of cells, adhered to a support matrix, which are capable of producing dopamine or a dopamine precursor to a subject suffering from schizophrenia. BACKGROUND [0003] Disorders of the nervous system comprise a wide variety of conditions, and can generally be separated into “neurological disorders” and “psychiatric disorders”. Neurological disorders can be characterized as the product of the death of nervous system cells. Examples of neurological disorders include Parkinson's Disease, which involves the death of dopamin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K35/30C12N5/08C12N11/02A61K35/12A61K35/23A61K35/44A61K47/32A61K47/34A61K47/36A61K47/42A61K48/00A61P25/18C12N5/06C12N5/10C12R1/91
CPCA61K35/12A61K35/36A61K48/00A61K35/30A61P25/18
Inventor ALLEN, RICHARD C.CORNFELDT, MICHAEL
Owner TITAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com